The therapeutic effect of modified Yu Ping Feng San on idiopathic sweating in end‐stage cancer patients during hospice care

End‐stage cancer patients frequently suffer from idiopathic sweating of unknown cause. This study was to evaluate the effect (primary endpoint) of modified Yu Ping Feng San on idiopathic sweating and adverse reactions (secondary endpoint). Thirty two end‐stage cancer patients receiving hospice care, with exclusion criteria including sweating due to known causes and taking drugs which may affect the sweating threshold were enrolled. Patients received modified Yu Ping Feng San for 10 consecutive days. The quantitative measurement of sweating showed 26 patients (81.3%) had complete remission of sweating, and the average time required to reach 50% reduction was 4.6 days. The visual analog scale (VAS) sweating score estimated by patients and care‐givers showed that the mean reductions were 8.4 and 9.1 points, respectively. An increase in appetite was experienced by 65.6% of patients, after administration of modified Yu Ping Feng San. The most prevalent treatment‐related complications were nausea (15.6%), diarrhea (9.3%) and allergy (3.1%) without severity greater than grade 2, and these were reversible after cessation of treatment. These results suggest that modified Yu Ping Feng San is a safe and effective treatment for idiopathic sweating of unknown cause in end‐stage cancer patients. Copyright © 2008 John Wiley & Sons, Ltd.

[1]  E. Ernst.  The prevalence of complementary/Alternative medicine in cancer , 1998, Cancer.

[2]  H. Tsay,et al.  Determination of the components in a Chinese prescription, yu-ping-feng san, by RAPD analysis. , 1998, Planta medica.

[3]  K. Eguchi,et al.  Nationwide survey on complementary and alternative medicine in cancer patients in Japan. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D L Kellogg,et al.  Role of nitric oxide in the vascular effects of local warming of the skin in humans. , 1999, Journal of applied physiology.

[5]  D. Marlin,et al.  Effects of Nitric Oxide Inhibition on Thermoregulation during Exercise in the Horse , 1997, Annals of the New York Academy of Sciences.

[6]  D. Walsh,et al.  The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients , 2000, Supportive Care in Cancer.

[7]  A. Bjorksten,et al.  Tramadol Reduces the Sweating, Vasoconstriction, and Shivering Thresholds , 1998, Anesthesia and analgesia.

[8]  R. Freedman,et al.  Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. , 2000, Fertility and sterility.

[9]  J. Johnson,et al.  Modification of active cutaneous vasodilation by oral contraceptive hormones. , 1997, Journal of applied physiology.

[10]  M. Joyner,et al.  Nitric oxide and neurally mediated regulation of skin blood flow during local heating. , 2001, Journal of applied physiology.

[11]  M. Joyner,et al.  Effects of nitric oxide synthase inhibition on cutaneous vasodilation during body heating in humans. , 1998, Journal of applied physiology.

[12]  C. E. Johnston,et al.  Clonidine decreases vasoconstriction and shivering thresholds, without affecting the sweating threshold , 1997, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[13]  D. Sessler,et al.  Clonidine Increases the Sweating Threshold, but Does Not Reduce the Gain of Sweating , 1996, Anesthesia and analgesia.

[14]  P. Fayers,et al.  Quality of life in palliative cancer care: results from a cluster randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.